In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AAA/EVAR device firm TriVascular Technologies' IPO nets $83.4mm

Executive Summary

Only five months after returning to venture investors for a $40mm Series E round, TriVascular Technologies Inc. (minimally invasive devices for abdominal aortic aneurysms (AAAs)) netted $83.4mm in its initial public offering of 7.5mm shares (including the overallotment) at $12, below its planned $13-15 price range. Certain existing backers indicated an interest in buying $38mm of the IPO shares.

Deal Industry
  • Biotechnology
  • Medical Devices
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
      • Surgical Sealants
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies